Samsung Biologics
Incheon, South Korea samsungbiologics.com From their website, Nov 2026
- GMP
Work here? Claim this listing
About
Samsung Biologics is a biologics CDMO that provides development, manufacturing, and analytical testing services for biopharmaceutical companies. It supports programs from late discovery and cell line development through commercial drug substance, drug product, and aseptic fill-finish manufacturing from sites in Incheon, South Korea, and Rockville, Maryland.
Services
Organoid Services
Uses patient-derived tumor organoids, AI-based predictive analysis, and multi-omics data for precision drug screening, target identification, and translational research.
Late Discovery Services
Provides proprietary platforms to accelerate transition from research to development, including bispecific antibody discovery and developability assessment.
Cell Line Development
Develops cell lines for biologics and complex molecules using proprietary CHO platforms and screening workflows to support IND/IMPD submissions.
Cell line development
Process Development
Offers phase-appropriate upstream, downstream, and formulation development using QbD, design-of-experiment methods, and in-house analytics.
Analytical Development
Develops analytical methods and supports characterization, comparability, stability, and method transfer for biologics programs.
Non-GMP and CGMP Manufacturing
Manufactures preclinical, clinical, and commercial biologics with non-GMP and CGMP workflows across multiple batch sizes.
CDMO: development & manufacturing
Drug Substance Manufacturing
Provides clinical-to-commercial drug substance manufacturing with single-use and stainless-steel bioreactor options.
CDMO: development & manufacturing
Drug Product Manufacturing
Provides aseptic fill-finish drug product manufacturing for biologics and small molecules, including vials and prefilled syringes.
CDMO: development & manufacturing
8 more services
- Bioconjugation Development and Manufacturing
- mRNA Manufacturing and Development Services
- Analytical Testing Services
- Quality and GMP Services
- Non-GMP / CGMP Manufacturing
- Aseptic Fill-Finish
- Bioconjugation
- mRNA Services
- Turnaround
- 30 days to 285 days
- What to send
- 80 mg minimum material for DEVELOPICK®
- Patient tumor tissue for organoid generation
- Parental antibody sequences for S-DUAL®
- Minimums and prices
- Competitive pricing for S-DUAL® (no amount stated)
Capabilities
- Assays and studies
- Process development
- Analytical development
- mRNA
- ADCs
- Fill-finish
- Peptides
24 more
- CHO
- LNP
- Lyophilization
- qPCR
- Protein concentration
- Titer
- N-glycan profile
- Peptide mapping
- iCIEF
- Flow cytometry
- Bioassay
- Purity
- CE-SDS
- Residual host cell DNA
- Residual host cell protein
- Residual protein A
- Potency
- Sterility
- Endotoxin
- Precision drug screening
- Developability assessment
- Analytical testing
- Mycoplasma test
- In vitro virus test
- Scale and capacity
- 845 kL total capacity
- 1,000 L to 15,000 L bioreactor capacity
- 0.1 L to 200 L single-use mRNA batch capacity
- 5 L to 2,500 L batch sizes for drug product
- Up to 350,000 vials per day
- Up to 500 L train for bioconjugation
10 more
- 50 L and 200 L single-use bioreactors
- 2R-50R aseptic vial filling for preclinical studies
- 5–15 kL drug substance scale
- ≤2 kL small-scale drug substance
- Bio Campus II scheduled for completion in 2032
- 50 L and 200 L single-use bioreactor manufacturing
- 1 kL manufacturing support
- 5–15 kL large-scale drug substance
- 2R-50R aseptic vial filling
- Bio Campus II completion scheduled for 2032
- Therapeutic areas
- Oncology
- Precision oncology
Instruments and platforms
- Ambr 15
- 2L STR
- qPCR
- ELISA
- Flow cytometry
- Octet® HTX
- AKTA
- UF/DF equipment
Modalities and species
- Modalities
- Small molecule
- Antibody
- Bispecific
- ADC
- Peptide
- Oligonucleotide
3 more
- mRNA
- Recombinant protein
- LNP / formulation
- Species and models
- Patient-derived tumor organoids
- 3D tumor models
- Colorectal cancer
- Lung cancer
- Liver cancer
- Gastric cancer
8 more
- Breast cancer
- CHO cell lines
- CHOZN cell lines
- MRC-5
- Vero
- CHO-K1
- A9
- NIH3T3
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Scope: biologics manufacturing and fill-finish
Company
- Type
- CRDMO
- Founded
- 2011
- Size
- 1001-5000 employees
Locations
- Based in
- Incheon, South Korea
- Sites
- Rockville, United States
- Yeonsu-gu, Republic of Korea
- Serves
- Global, Europe, Asia, U.S., Asia-Pacific